Gujarat Themis Biosyn closes ₹1,300 cr Japan CDMO buy

Deal closure: GTBL takes full control of MBJ

Gujarat Themis Biosyn Limited (GTBL) has completed the acquisition of a 100% equity stake in Japan-based MicroBiopharm Japan Co., Ltd. (MBJ). The transaction was closed through its wholly owned subsidiary, Themis Biosyn Japan Limited. GTBL described the closing as a milestone that provides immediate access to Japan’s regulated biopharma ecosystem. The acquisition positions GTBL deeper into contract development and manufacturing organization (CDMO) services, alongside its existing fermentation-led operations. The company had earlier communicated that the transaction would be carried out through a Japan-incorporated structure and was subject to customary approvals and conditions. With the closing now completed, the deal moves from a planned expansion to an operational integration exercise.

How the transaction was executed

The acquisition was executed via Themis Biosyn Japan Limited, a wholly owned subsidiary of GTBL. GTBL had incorporated the Japanese subsidiary on May 19, 2026 as part of the acquisition plan. On May 22, 2026, the company announced it would acquire 100% equity in MBJ from funds managed by T Capital Partners, a Japan-based private equity firm. The stated deal value at announcement was approximately JPY 21.5 billion, presented as roughly ₹1,300 crore. GTBL also indicated that a special purpose vehicle (SPV) would be incorporated in Japan to execute the agreement. The company had guided that the transaction would close during Q2 FY2027, subject to regulatory approvals in Japan and customary closing conditions.

Funding mix: ₹475 crore equity and ₹745 crore inter-company loan

GTBL disclosed that the acquisition closing involved two primary funding legs routed to the Japanese subsidiary. First, GTBL invested ₹475 crore as a capital contribution in Themis Biosyn Japan Limited to fund the acquisition. Second, an additional ₹745 crore was extended as an inter-company loan to the same subsidiary to enable completion of the transaction. Together, these disclosed components add up to ₹1,220 crore of the closing outlay. GTBL had also earlier communicated that the deal would be funded through a mix of debt and equity. In addition, the company had indicated financing flexibility, including the possibility of a qualified institutional placement (QIP) of up to ₹1,000 crore, alongside debt arrangements.

NCD placement: ₹585 crore raised on September 16, 2026

The company said the transaction was supported by a private placement of secured non-convertible debentures (NCDs). The NCDs were allotted on September 16, 2026, with a total raised amount of ₹585 crore. The NCD issuance forms part of the funding architecture around the acquisition and associated steps needed for closure. While the company has referenced a debt and equity mix, the disclosed items around the closing specifically mention the capital contribution, inter-company loan, and the NCD allotment date and amount. The previously shared planning note around “financing mix (debt/equity) to be finalized at closing” reflects that the company had been working through final approvals and structure near end-August 2026.

What MBJ brings: fermentation and CDMO capabilities

GTBL has positioned MBJ as a way to broaden capabilities across fermentation, biologics, precision fermentation, and CDMO services. In its earlier communication around the deal, the company framed the move as a shift from a fermentation-led intermediates business toward a higher-value CDMO platform. MBJ was described as having more than six decades of experience in fermentation, microbial-based research, development, and manufacturing of pharmaceuticals and specialty chemicals. GTBL also cited estimated FY2026 revenue for MBJ of around ₹570 crore (presented alongside a figure of JPY 9.5 billion). The combination of Japan-based infrastructure and GTBL’s fermentation heritage is central to the strategic rationale presented.

Timeline: from incorporation to completion

The acquisition process unfolded across several distinct steps, with the company providing multiple public markers.

Market reaction: stock moved on the acquisition news

GTBL’s share price reaction was recorded around the initial announcement phase. The stock was reported to have surged 6.11% to ₹391.40 following the acquisition announcement of MBJ for about JPY 21.5 billion (nearly ₹1,300 crore). In another reported snapshot, GTBL shares rose about 4.01% in opening trade, with the stock quoting at ₹383.65 at 09:21 hrs on the BSE, up ₹14.80. These moves reflect a positive near-term market response to the strategic expansion plan and the scale of the transaction relative to the company’s base business. However, the longer-term market outcome will depend on integration and execution, which typically become clearer over subsequent quarters.

Context: GTBL’s fermentation roots and historic milestones

GTBL operates in the development, manufacturing, and marketing of fermentation-based pharmaceutical intermediates and APIs across key therapeutic segments in India. The company has previously highlighted technical and financial collaboration with Yuhan Corporation, South Korea. It also stated it became India’s first company to start commercial production of the anti-tuberculosis drug Rifampicin. This history matters because MBJ’s positioning in fermentation and microbial-based manufacturing aligns with GTBL’s established competency base. The acquisition therefore reads as an expansion in geography and customer access, rather than a shift into an unfamiliar scientific platform.

Key numbers at a glance

The deal’s scale and funding disclosures are central to how investors will track the transaction over the next few reporting cycles.

Why the closing matters and what to monitor next

The closing gives GTBL an operating foothold in Japan, a market the company described as a regulated biopharma ecosystem. For a fermentation-focused Indian pharma inputs developer, the move potentially widens the addressable customer base through CDMO contracting and adds capabilities that the company has explicitly listed, including biologics and precision fermentation. From a monitoring perspective, investors will likely focus on how the funding structure flows through the consolidated balance sheet and how the Japanese operations contribute to revenue and profitability over time. GTBL had earlier communicated the acquisition as an EPS-accretive move, but the article text does not provide post-closing EPS math or timelines.

Conclusion

GTBL’s completion of the MBJ acquisition marks a significant cross-border step, backed by a defined funding package that includes ₹475 crore of equity contribution, ₹745 crore of inter-company loans, and support from a ₹585 crore NCD allotment dated September 16, 2026. The deal, previously communicated at about ₹1,300 crore, aligns with the company’s stated intent to expand from fermentation-based intermediates toward a higher-value CDMO platform. The next set of hard data points will come from subsequent disclosures on integration milestones and reported financial contributions from the Japan business.